Pradefovir: A Prodrug That Targets Adefovir to the Liver for the Treatment of Hepatitis B
Citations Over TimeTop 10% of 2008 papers
Abstract
Adefovir dipivoxil, a marketed drug for the treatment of hepatitis B, is dosed at submaximally efficacious doses because of renal toxicity. In an effort to improve the therapeutic index of adefovir, 1-aryl-1,3-propanyl prodrugs were synthesized with the rationale that this selectively liver-activated prodrug class would enhance liver levels of the active metabolite adefovir diphosphate (ADV-DP) and/or decrease kidney exposure. The lead prodrug (14, MB06866, pradefovir), identified from a variety of in vitro and in vivo assays, exhibited good oral bioavailability (F = 42%, mesylate salt, rat) and rate of prodrug conversion to ADV-DP. Tissue distribution studies in the rat using radiolabeled materials showed that cyclic 1-aryl-1,3-propanyl prodrugs enhance the delivery of adefovir and its metabolites to the liver, with pradefovir exhibiting a 12-fold improvement in the liver/kidney ratio over adefovir dipivoxil.
Related Papers
- → Pradefovir: A Prodrug That Targets Adefovir to the Liver for the Treatment of Hepatitis B(2008)73 cited
- → Oral bioavailability of 17 β-estradiol and prodrugs tested in rats, pigs and dogs(1996)8 cited
- → Synthesis and relative bioavailability of meptazinol benzoyl esters as prodrugs(2005)3 cited
- Prodrug Decision of Novel Genistein Sulfonate and Its Bioavailability in Rats(2012)
- Adefovir dipivoxil (Preveon) new results with hepatitis B, HIV.(1998)